494 related articles for article (PubMed ID: 31873772)
21. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
22. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate.
Chen XX; Li ZG; Wu HX; Zhao DB; Li XF; Xu JH; Tao Y; Yang NP; Hu SX; Huang AB; Jiang LD; Wang GC; Zhang X; Bao CD
Clin Rheumatol; 2016 Sep; 35(9):2175-83. PubMed ID: 27184046
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
[TBL] [Abstract][Full Text] [Related]
25. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
26. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
[TBL] [Abstract][Full Text] [Related]
29. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study.
Xu X; Liu X; Zheng W; Xiao J; Li X; Wu L; Zou L; Ouyang Q; Shangguan Y; Lin K; Dai X; Chen Y; Xu Y; Wu J; Lu M
Front Pediatr; 2022; 10():992932. PubMed ID: 36299687
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
Singh SK; Singnarpi SR
Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
[TBL] [Abstract][Full Text] [Related]
33. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
34. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
[TBL] [Abstract][Full Text] [Related]
35. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Leonardi C; Kerdel F; Mehlis S; Olds M; Williams DA
Br J Dermatol; 2011 Sep; 165(3):652-60. PubMed ID: 21574983
[TBL] [Abstract][Full Text] [Related]
37. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
38. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
Zachariae C; Mørk NJ; Reunala T; Lorentzen H; Falk E; Karvonen SL; Johannesson A; Claréus B; Skov L; Mørk G; Walker S; Qvitzau S
Acta Derm Venereol; 2008; 88(5):495-501. PubMed ID: 18779890
[TBL] [Abstract][Full Text] [Related]
39. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
40. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
